Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

Abstract The poly(ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended‐release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib‐ER up t...

Full description

Saved in:
Bibliographic Details
Main Authors: Theresa L. Werner, Jasgit Sachdev, Elizabeth M. Swisher, Martin Gutierrez, Muaiad Kittaneh, Mark N. Stein, Hao Xiong, Martin Dunbar, Danielle Sullivan, Philip Komarnitsky, Mark McKee, Antoinette R. Tan
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Cancer Medicine
Subjects:
BRCA
breast carcinoma
extended‐release formulation
ovarian carcinoma
PARP inhibitor
veliparib
Online Access:https://doi.org/10.1002/cam4.1488
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items